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An estimated 20 million Americans may have heart failure
without overt symptoms (stage B and early stage C), yet this
syndrome remains poorly understood, and therapeutic op-
tions are largely limited to lifestyle and risk factor modifi-
cations (1,2). Although therapy with neurohormonal blockers
should be considered for these patients, unless contraindi-
cated, this recommendation is predominantly extrapolated
from studies with systolic heart failure patients having
minimal signs and symptoms. Therapies for isolated dia-
stolic dysfunction are lacking, even though nearly 50% of
heart failure is attributed to impaired diastolic rather than
impaired systolic heart function (3,4). Understanding the
pathophysiology of these pre-clinical stages of the disease is
crucial, as treatment success is often considered the relief or
prevention of systemic (venous) congestion (5).
See page 2095
Most studies focus on early stage underlying structural
and molecular changes leading to failing myocardium, but
less is known about its precise role in cardiorenal interac-
tions as a prelude to overt signs and symptoms of heart
failure. Historically, both symptomatic systolic and diastolic
heart failure exhibit the tendency to retain water and salt,
which is often explained by the cardiorenal and cardiocir-
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support from Abbott Laboratories.culatory heart failure models (6–10). However, the inter-
twining of the cardiorenal and humoral responses to achieve
sodium and fluid homeostasis remains poorly characterized
in early heart failure stages. In this issue of the Journal,
McKie et al. (11) reported the possible contribution of
impaired renal cyclic guanosine monophosphate (cGMP)
activation in generating natriuretic response during volume
expansion in systolic or diastolic dysfunction patients with-
out overt congestion. Their results suggest that the renal
response to volume expansion is similarly impaired in both
systolic and diastolic heart failure, leading to an inability to
produce the compensatory increase in natriuresis seen in
normal subjects. These observations support the concept
that congestion may be driven predominantly by impaired
renal reserve rather than by progressive cardiac insufficiency.
We congratulate the authors in their efforts to further
elucidate the pathophysiology of heart failure as it relates to
the vulnerability toward congestion. Nevertheless, it is
important to recognize that while the authors described
these subjects as being “pre-clinical,” the average B-type
natriuretic peptide (BNP) of 110 pg/ml and the majority of
patients being treated with standard heart failure medica-
tions may reflect a population that already has some degree
of underlying symptomatic cardiac involvement, despite
being able to walk 450 m (i.e., they are already in stage C
heart failure but with minimal symptoms). Their data
underscore how incorrectly disease severity is identified
based on clinical or echocardiographic judgment alone,
which clearly overlooks underlying vulnerability. The results
also imply that conventional signs and symptoms (even with
systemic or imaging measures) may lack the sensitivity to
identify vulnerability of such impaired renal reserve without
the provocation of volume expansion.
Growing evidence has suggested that hypervolemia by
itself, or at least the blunted reaction to hypervolemia, is
independently associated with adverse outcomes (5). Several
reports recently suggested increased venous pressure to be
the culprit hemodynamic lesion to account for worsening
renal function in chronic advanced heart failure patients
(12,13). Indeed, an index event damages heart function,
leading to a decreased effective arterial blood volume, which
is detected by several mechanoreceptors in the left ventricle,
aortic arch, and carotid sinus as well as the kidney’s
baroreceptorlike juxtaglomerular apparatus. Reduced recep-
tor activation can lead to an increase in sympathetic outflow
from the central nervous system, activation of the renin-
angiotensin-aldosterone system, nonosmotic release of ar-
ginine vasopressin, as well as the stimulation of thirst (5,6).
The resulting venous congestion will further impair renal
function (12–14). Although venous congestion was notably
absent in the present study according to the inclusion
criteria, patients in the heart failure subgroups had higher
natriuretic peptide levels and higher tissue Doppler E/E=
ratio, both indicative of at least some augmentation in
intravascular filling pressures. Nevertheless, with volume
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even in the setting of systolic and diastolic dysfunction,
emphasizing the large capacity that probably the venous
bed, splanchnic circulation, and the kidneys can handle with
regard to volume load before overt congestion occurs. In
other words, volume expansion seems to be well tolerated in
compensated heart failure patients despite a blunted renal
reserve. It is therefore unlikely that the impaired renal
response to volume expansion is linked to chronic elevation
of venous pressures in the “pre-clinical” stages of heart
failure.
In addition, these intriguing data challenge conventional
wisdom that increased diuresis in response to volume
expansion is mediated through sensitive detection of in-
creased filling pressures in the heart or great vasculature. In
fact, the discordance between cardiac performance and renal
response to volume expansion challenges once more the
notion that, in heart failure, hypoperfusion of the kidney as
a result of poor forward flow is responsible for this blunted
response. Rather, the subsiding homeostatic adjustments at
the level of renal tubules may be the early defects that lead
to progressive congestion. As a result, the search for
pathologic mechanisms that trigger such defects should be
the focus. Further studies are needed to investigate if this
blunted response is primarily renal in origin and indepen-
dent of the cardiac dysfunction or actually directly inter-
twined with the underlying cardiac abnormalities, perhaps as a
result of renin-angiotensin-aldosterone system/sympathetic
nervous system up-regulation.
Importantly, the impaired renal excretory response to
volume expansion is rescued by exogenous subcutaneous
recombinant human B-type natriuretic peptide (BNP) in-
jections, again independent of the heart failure subtype (11).
However, the degree of plasma and urinary cyclic guanosine
monophosphate responses to BNP in normal subjects was
still far greater than that observed in patients with heart
failure, and may indirectly suggest that even an increase in
the overall circulating “functional” BNP (through exoge-
nous administration) might not completely overcome the
blunted renal natriuretic response (rather than an absolute
lack of sufficient circulating functional BNP). Whether
defects in specific natriuretic peptide receptors or post-
receptor mechanisms could account for these findings may
warrant further investigation. However, one has to be
careful how to interpret these results, as more than two-
thirds of heart failure patients were taking neurohormonal
therapy, which might have confounded the response to
volume expansion as well.
These intriguing observations raise questions about our
current management strategy for heart failure, especially in
the early stages of the disease, which have been focused
primarily on systemic neurohormonal blockade. These find-
ings imply that potentiating the natriuretic peptide systemmight serve as an important therapeutic target to improve
the failing cardiorenal interactions in heart failure before
overt congestion ensues. The challenge is to identify treat-
ment strategies that can selectively improve renal natriuretic
responses, particularly in patients with diminished reserve.
On the basis of insights from McKie et al. (11), it is perhaps
more important to revisit the delicate balance that the
kidney brings to the syndrome of heart failure.
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